海南葫芦娃药业集团股份有限公司 审计报告及财务报表 二〇二四年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行企业 报告编码:沪255M33 海南葫芦娃药业集团股份有限公司 审计报告及财务报表 (2024 年 01 月 01 日至 2024 年 12 月 31 日止) | | 目录 | 页次 | | --- | --- | --- | | P | 审计报告 | 1-6 | | | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | ર-୧ | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-104 | 言会计师事务所(特殊普通合 INA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTAN 审计报告 信会师报字[2025]第 ZA12624 号 海南葫芦娃药业集团股份有限公司全体股东: 一、 保留意见 我们审计了海南葫芦娃药业集团股份有限公司(以下简称 ...

Financial Performance - The company reported a net profit attributable to shareholders of -27,445.73 million RMB for the year 2024, while the parent company achieved a net profit of 963.24 million RMB[6]. - Total operating revenue for 2024 was 1,413,548,352 RMB, representing a decrease of 21.26% compared to 2023[23]. - The company's main business revenue was 1,406,954,599 RMB, down from 1,782,244,429 RMB in the previous year, indicating a significant decline in operational performance[23]. - The net profit attributable to shareholders decreased by 31.64% compared to the beginning of the period, primarily due to a significant reduction in undistributed profits[26]. - The basic earnings per share for 2024 is -0.69 yuan, a decrease of 2,400.00% compared to 0.03 yuan in 2023[25]. - The net profit attributable to the parent company was -274.46 million yuan, a year-on-year decline of 2,629.23%[36]. - The net profit after deducting non-recurring items for the fourth quarter was -165,681,549.13 yuan, further emphasizing the financial difficulties faced[31]. - The weighted average return on equity decreased to -31.66% in 2024 from 1.06% in 2023, indicating a significant decline in profitability[25]. - The company reported a net loss of -158,641,405.61 yuan in the third quarter, highlighting ongoing financial challenges[31]. - The net cash flow from operating activities was CNY -149,115,614.99, a decline of 627.80% compared to the previous year[91]. Operational Highlights - The company has faced various risks in its future operations, which are detailed in the management discussion section of the report[8]. - The company has maintained compliance with decision-making procedures regarding external guarantees[8]. - The audit report from Lixin Accounting Firm expressed a qualified opinion on the financial statements[5]. - The total assets at the end of the reporting period are 3,060,548,675.78 yuan, reflecting an increase of 0.85% compared to 2,939,486,655 yuan at the end of 2022[24]. - The cash flow from operating activities showed a recovery in the fourth quarter with a positive net cash flow of 55,496,370.54 yuan[31]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has established deep cooperation with several renowned research institutions to enhance its R&D capabilities[42]. Research and Development - R&D investment reached 249.54 million yuan, an increase of 58.63% year-on-year, emphasizing the company's commitment to innovation[41]. - The company is actively developing new pediatric products with better stability and adaptability, targeting high-end international markets[85]. - The company has 116 ongoing research projects, including 7 Class 1 traditional Chinese medicine innovative drugs and 8 Class 2 chemical new drugs[126]. - The company has established a comprehensive marketing system covering OTC products and prescription drug promotion, expanding to fourth-level terminals[88]. - The company is focusing on optimizing traditional formulations for pediatric use, developing new dosage forms such as oral liquids and nebulized inhalants[126]. - The company has cumulatively obtained 112 patents, enhancing its technological barriers[127]. - The company is committed to ongoing research and development to innovate and improve its therapeutic offerings[134]. Market Strategy - The company aims to transform from treatment to comprehensive health management for children, leveraging its brand advantages in the market[57]. - The company is positioned to benefit from the growing demand for children's health products, driven by increasing consumer health awareness[63]. - The company has established a comprehensive quality traceability system in its new manufacturing plant, ensuring real-time monitoring from raw material intake to product shipment[72]. - The marketing strategy focuses on enhancing brand awareness and influence through customized services and academic value promotion[73]. - The company is exploring potential mergers and acquisitions to enhance its market position[183]. - The company plans to expand its market presence significantly in the next fiscal year[183]. Governance and Compliance - The company has established a comprehensive governance structure, including a board of directors and various specialized committees to ensure effective decision-making[173]. - The company has disclosed a total of 146 reports on the Shanghai Stock Exchange in 2024, maintaining transparency and compliance with information disclosure regulations[177]. - The company has implemented measures to enhance compliance with securities regulations and improve awareness of operational responsibilities among its executives[192]. - The company plans to hold its annual shareholders' meeting on November 27, 2024, to elect a new independent director following the resignation of Wang Guihua[196]. - The company has established specialized committees to enhance governance and oversight, including the audit and compensation committees[199]. Sustainability Initiatives - The company is committed to sustainability initiatives, aiming for a 25% reduction in carbon footprint by 2025[183]. - The company is committed to sustainable development, achieving provincial-level green factory status for its production bases in Hainan and Guangxi[86]. - The company is focused on expanding its product portfolio with new drug approvals and clinical trials to enhance its market presence[134].

海南葫芦娃药业集团股份有限公司 董事会关于 2024 年度独立董事独立性情况的专项意见 根据证监会《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，并结合 独立董事出具的《关于独立性自查情况的报告》，海南葫芦娃药业集团股份有限 公司（以下简称"公司"）董事会，就公司 2024 年在任的独立董事王波、刘秋 云、王世贤、王桂华（离任）的独立性情况进行评估并出具如下专项意见： 经核查独立董事王波、刘秋云、王世贤、王桂华（离任）的任职经历以及签 署的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在 公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其 他可能妨碍其进行独立客观判断的关系。 因此，公司独立董事符合《上市公司独立董事管理办法》、《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》中对独立董事独立性的相关要求。 海南葫芦娃药业集团股份有限公司 董事会 2025 年 4 月 29 日 ...

海南葫芦娃药业集团股份有限公司 2024 年度独立董事述职报告 根据《公司法》、《证券法》、《上市公司独立董事管理办法》、《上海证券交 易所股票上市规则》、《上市公司自律监管指引第1号——规范运作》等法律法规以及 《海南葫芦娃药业集团股份有限公司章程》(以下简称"《公司章程》")、《海南葫芦 娃药业集团股份有限公司独立董事工作制度》等相关规定和要求，作为海南葫芦娃药业 集团股份有限公司（以下简称"公司"）独立董事，现就 2024年度履职情况述职如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 刘秋云，女，1979年出生，中国国籍，无境外永久居留权，本科学历，2016年8月 至2020年3月担任海南蛛王生物科技有限公司财务经理；2020年4月至2022年8月担任海 南自贸区珈宝置业集团有限公司财务总监；2022年9月至今担任海南迈迪能源科技有限 公司财务总监，2024年1月至今担任海南创亿高芯科技有限公司财务负责人，2022年11 月至今担任本公司独立董事。 （二）独立性情况说明 作为公司独立董事，本人及直系亲属、主要社会关系均不在公司或其附属企业任职， 未直接或间接持有公司股份，不在直 ...

海南葫芦娃药业集团股份有限公司 2024 年度独立董事述职报告 根据《公司法》、《证券法》、《上市公司独立董事管理办法》、《上海证券交 易所股票上市规则》、《上市公司自律监管指引第1号——规范运作》等法律法规以及 《海南葫芦娃药业集团股份有限公司章程》(以下简称"《公司章程》")、《海南葫芦 娃药业集团股份有限公司独立董事工作制度》等相关规定和要求，作为海南葫芦娃药业 集团股份有限公司（以下简称"公司"）独立董事，现就 2024年度履职情况述职如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 王桂华女士：1961年出生，中国国籍，无境外永久居留权，本科学历，副主任中药 师、执业药师。1983年8月至2000年10月，历任中国中药有限公司科技处、生产处、国 际合作部等部门管理职位；1996年9月至1998年10月，担任泰国东方药业有限公司中方 总经理；2000年10月至2005年8月，历任华禾药业股份有限公司企业管理部经理、总经 理助理、副总经理兼工会主席；2005年8月至今，担任中国中药协会秘书长兼全国中药 标准化技术委员会秘书长；2018年11月起担任本公司独立董事。在本公司任职期间 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 336,826,637.75, a decrease of 28.42% compared to CNY 470,529,089.59 in the same period last year[4] - Net profit attributable to shareholders was CNY 24,346,967.51, down 11.23% from CNY 27,426,051.99 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 15,976,507.07, reflecting a decline of 28.05% compared to CNY 22,203,613.06 in the previous year[4] - Basic and diluted earnings per share were both CNY 0.06, a decrease of 14.29% from CNY 0.07 in the previous year[4] - Total operating revenue for Q1 2025 was CNY 336.83 million, a decrease of 28.4% compared to CNY 470.53 million in Q1 2024[15] - Net profit for Q1 2025 was CNY 24.49 million, a decrease of 14.5% compared to CNY 28.56 million in Q1 2024[16] Cash Flow and Investments - The net cash flow from operating activities improved by 48.21%, amounting to -CNY 98,627,320.61, compared to -CNY 190,443,500.39 in the same period last year[4] - Cash flow from operating activities for Q1 2025 was negative CNY 98.63 million, an improvement from negative CNY 190.44 million in Q1 2024[18] - Investment activities resulted in a net cash outflow of CNY 36.90 million in Q1 2025, compared to a net outflow of CNY 91.93 million in Q1 2024[18] - Financing activities generated a net cash inflow of CNY 30.20 million in Q1 2025, a turnaround from a net outflow of CNY 1.69 million in Q1 2024[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,007,781,721.74, a slight increase of 1.46% from CNY 2,964,546,337.76 at the end of the previous year[5] - Current assets totaled RMB 1,247,388,127.87, compared to RMB 1,219,475,330.23 at the end of 2024, indicating an increase of about 2.3%[12][13] - Total liabilities reached RMB 2,240,048,877.98, slightly up from RMB 2,221,262,004.67, showing a growth of about 0.8%[14] - Total liabilities and equity amounted to CNY 3.01 billion, an increase from CNY 2.96 billion year-over-year[15] Shareholder Equity - Shareholders' equity attributable to shareholders was CNY 724,878,406.34, up 3.47% from CNY 700,553,123.09 at the end of the previous year[5] - The total equity attributable to the parent company increased to RMB 724,878,406.34 from RMB 700,553,123.09, indicating a growth of approximately 3.5%[14] Non-Recurring Gains and Other Income - The company recognized non-recurring gains of CNY 8,370,460.44 during the reporting period, primarily from government subsidies and other non-operating income[6] Research and Development - Research and development expenses in Q1 2025 were CNY 10.33 million, a significant drop of 78.9% from CNY 48.89 million in Q1 2024[15] Changes in Shareholder Participation - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[11] Accounting Standards - The company will implement new accounting standards starting from 2025, which will involve adjustments to the financial statements at the beginning of the year[19]

海南葫芦娃药业集团股份有限公司 2024 年度独立董事述职报告 根据《公司法》、《证券法》、《上市公司独立董事管理办法》、《上海证券交 易所股票上市规则》、《上市公司自律监管指引第1号——规范运作》等法律法规以及 《海南葫芦娃药业集团股份有限公司章程》(以下简称"《公司章程》")、《海南葫芦 娃药业集团股份有限公司独立董事工作制度》等相关规定和要求，作为海南葫芦娃药业 集团股份有限公司（以下简称"公司"）独立董事，现就 2024年度履职情况述职如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 王世贤，男，1976年出生，中国国籍，无境外永久居留权，本科学历，2007年10月 至2021年7月担任海南正益律师事务所专职律师，2010年5月至2020年11月担任海南国际 仲裁院仲裁员，2021年7月至今担任海南晋世律师事务所合伙人、主任，2022年11月至 今担任本公司独立董事。 （二）独立性情况说明 作为公司独立董事，本人及直系亲属、主要社会关系均不在公司或其附属企业任职， 未直接或间接持有公司股份，不在直接或间接持有公司已发行股份5%或5%以上的股东单 位任职。本人不曾为公司或公司附属 ...

海南葫芦娃药业集团股份有限公司 2024 年度独立董事述职报告 根据《公司法》、《证券法》、《上市公司独立董事管理办法》、《上海证券交 易所股票上市规则》、《上市公司自律监管指引第1号——规范运作》等法律法规以及 《海南葫芦娃药业集团股份有限公司章程》(以下简称"《公司章程》")、《海南葫芦 娃药业集团股份有限公司独立董事工作制度》等相关规定和要求，作为海南葫芦娃药业 集团股份有限公司（以下简称"公司"）独立董事，现就 2024年度履职情况述职如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 王波先生：1960年6月出生，中国国籍，无境外永久居留权，本科学历冶金机械专 业。现任北京秦脉医药咨询有限责任公司董事长、总经理；石药集团有限公司独立董事、 悦康药业集团股份有限公司独立董事。2024年11月27日起担任本公司独立董事，目前兼 任石药集团有限公司、悦康药业集团股份有限公司独立董事。 （二）独立性情况说明 作为公司独立董事，本人及直系亲属、主要社会关系均不在公司或其附属企业任职， 未直接或间接持有公司股份，不在直接或间接持有公司已发行股份5%或5%以上的股东单 位任职。本人不曾为公司 ...

Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. announced that its stock will be subject to risk warnings due to an audit report indicating internal control issues, leading to a change in stock abbreviation and a reduction in daily price fluctuation limits [1][4]. Group 1: Stock Trading and Risk Warning - The company's stock will be traded under the abbreviation "ST Huluwa" starting April 30, with the stock code remaining "605199" [1]. - The daily price fluctuation limit will be adjusted from 10% to 5% [1]. Group 2: Financial Reporting Issues - The risk warning stems from the 2023 annual report, which revealed issues such as premature revenue recognition and unusual sales prices, resulting in inaccurate financial data disclosures [4]. - The audit report from Lixin Certified Public Accountants indicated that the company had not provided complete financial materials related to the restatement of its 2023 financial statements, leading to a qualified opinion on the 2024 financial statements [4]. Group 3: Additional Concerns - Lixin's report disclosed that the controlling shareholder provided financial support to customers through personal bank accounts, raising concerns about the company's receivables [6]. - Some of the top 10 customers by accounts receivable showed no payments or minimal payments after the reporting period [6]. - The company purchased 12 R&D projects from Hainan Zhongwang Medical Technology Development Co., Ltd. for over 60 million yuan, with familial ties between the legal representative of Zhongwang and one of Huluwa's actual controllers, raising potential conflicts of interest [6]. - Huluwa has committed to taking corrective measures to address internal control deficiencies and improve financial compliance [6].

葫芦娃：公司股票实施其他风险警示 简称变更为ST葫芦娃 智通财经4月28日电，葫芦娃(605199.SH)公告称，因最近一个会计年度财务报告内部控制被出具无法表 示意见或否定意见的审计报告，公司股票交易触及其他风险警示情形。公司A股股票简称自2025年4月 30日起由"葫芦娃"变更为"ST葫芦娃"，证券代码仍为"605199"，实施风险警示后股票价格的日涨跌幅限 制为5%。公司将继续深入自查内部控制存在的缺陷，加强财务规范性，规范从合同签订、货物交付、 销售回款等收入确认的各个环节操作。 ...